Treatment outcome and prognostic factor in fit elderly patients with multiple myeloma received frontline induction of bortezomib based regimen (PAD or VCD)
Sign Up to like & getrecommendations! Published in 2017 at "Translational cancer research"
DOI: 10.21037/13818
Abstract: Background: Few clinical trials have head to head compared bortezomib, doxorubicin and dexamethasone (PAD) and bortezomib, cyclophosphamide and dexamethasone (VCD) regimen in multiple myeloma (MM), especially for the elderly patients. Methods: In this study, we… read more here.
Keywords: pad vcd; frontline induction; multiple myeloma; bortezomib ... See more keywords
Machine Learning Applicability for Classification of PAD/VCD Chemotherapy Response Using 53 Multiple Myeloma RNA Sequencing Profiles
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.652063
Abstract: Multiple myeloma (MM) affects ~500,000 people and results in ~100,000 deaths annually, being currently considered treatable but incurable. There are several MM chemotherapy treatment regimens, among which eleven include bortezomib, a proteasome-targeted drug. MM patients… read more here.
Keywords: chemotherapy; pad vcd; multiple myeloma; rna sequencing ... See more keywords